预约演示
更新于：2025-07-26
Atezolizumab
阿替利珠单抗
更新于：2025-07-26
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2016-05-18), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、附条件批准 (中国)、孤儿药 (澳大利亚)、优先审评 (澳大利亚)、优先审评 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 122091L
来源: *****
Sequence Code 4720027H
来源: *****
关联
858
项与 阿替利珠单抗 相关的临床试验NCT07049848
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
NCT07018947
A Phase II, Randomized, Open-label, National, Multicenter Study Evaluating the Efficacy and Safety of the Combination of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in Hepatocellular Carcinoma (ASPIRE)
NCT07053007
Phase I Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
100 项与 阿替利珠单抗 相关的临床结果
登录后查看更多信息
100 项与 阿替利珠单抗 相关的转化医学
登录后查看更多信息
100 项与 阿替利珠单抗 相关的专利（医药）
登录后查看更多信息
4,621
项与 阿替利珠单抗 相关的文献（医药）2025-12-01CANCER CHEMOTHERAPY AND PHARMACOLOGY
Potential role of endothelial dysfunction in hypertension and proteinuria in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a pilot prospective observational study
Article
作者: Kudo, Kenzo ; Nihei, Satoru ; Oikawa, Takayoshi ; Saito, Kazuki ; Asaka, Junichi ; Ikeda, Tatsuki ; Asahi, Koichi
PURPOSE:
Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). Its inhibition of VEGF signaling may lead to proteinuria due to endothelial dysfunction but the association between endothelial function and clinical outcomes has not been established. This study aimed to investigate vascular endothelial function in patients with HCC receiving atezolizumab plus bevacizumab, and to assess the correlation between reactive hyperemia index (RHI) and adverse renal outcomes.
METHODS:
This pilot prospective observational study included 20 patients with HCC who received atezolizumab plus bevacizumab. We used reactive hyperemia-peripheral arterial tonometry (RH-PAT) and evaluated vascular endothelial function on the basis of RHI. RHI, blood pressure, and proteinuria were recorded at baseline and at 3 and 6 months after initiation of atezolizumab plus bevacizumab treatment. Statistical analyses were performed to investigate the relationship of RHI to blood pressure and proteinuria.
RESULTS:
Following initiation of atezolizumab plus bevacizumab treatment, systolic blood pressure and urine protein-creatinine ratio increased significantly, and RHI decreased. Patients with borderline or low baseline RHI had a higher incidence of grade ≥ 2 proteinuria than those with normal baseline RHI but not hypertension. A significant inverse correlation was found between RHI and urine protein-creatinine ratio.
CONCLUSION:
Bevacizumab administration may cause endothelial dysfunction in patients with HCC. The vascular endothelial function status before and during atezolizumab plus bevacizumab treatment is associated with the risk of bevacizumab-induced proteinuria.
2025-10-01REPRODUCTIVE TOXICOLOGY
Exploring the toxicological mechanisms of atrazine in prostate cancer by network toxicology and molecular docking
Article
作者: Mi, Jinwen ; Wei, Guanghui ; Hong, Yifan ; Wang, Siyuan ; Wu, Shengde
Atrazine (ATZ) is the second most used herbicide against broadleaf and grassy weeds worldwide. ATZ persists in soil and water due to its long half-life, and is considered an endocrine disrupting chemical for humans. Epidemiological studies have indicated an intimate relationship between ATZ and the pathogenesis of prostate cancer (PCa). However, the underlying toxicological mechanisms remain barely elucidated. Leveraging the CTD, GeneCards, OMIM, PharmGKB, and TTD databases, we identified 154 target genes associated with ATZ exposure and PCa. Using STRING and Cytoscape tools, a PPI network was constructed, and five key genes involved in ATZ-induced PCa toxicity including TP53, JUN, AKT1, BCL2, and IL1B were extracted. Enrichment analysis of target genes highlighted the association of ATZ with pathways integral to PCa development. Expression analysis, ROC curve analysis, immune correlation analysis, and single-gene GSEA of these key genes confirmed their pivotal role in PCa biology. Furthermore, we employed Autodock Vina for molecular docking analysis, demonstrating strong binding between ATZ and the key genes. Collectively, our findings suggest that ATZ may serve as a potential environmental pollutant influencing the pathogenesis of PCa through interactions with key proteins and signaling pathways, offering a theoretical groundwork for the comprehensive prevention and medical management of PCa patients.
2025-09-01CHEMOSPHERE
Optimizing the atrazine degradation in g-C3N4@BiOBr/polyvinylidene fluoride photocatalytic membrane system
Article
作者: Gar Alalm, Mohamed ; Fuoad, Mohram ; Samy, Mahmoud ; Hamdy, Nourhan ; El-Geundi, Mohammad
In this study, g-C3N4@BiOBr heterostructure was synthesized at different molar ratios and dispersed into a polyvinylidene fluoride (PVDF) matrix for the photodegradation of atrazine (ATZ, herbicide) under visible light. The investigation of the photocatalytic performance of g-C3N4@BiOBr/PVDF membrane under different operating parameters has not been extensively studied in the literature. Thus, this study focused on the optimization of the g-C3N4@BiOBr/PVDF membrane degradation system and deep exploration of the degradation mechanism. Various analyses characterized the as-prepared catalysts and membranes, including XRD, TEM, FTIR, EDX, SEM, XPS, and DRS. The g-C3N4@BiOBr/PVDF membrane (g-C3N4@BiOBr at a mole ratio 1:3) showed the highest photocatalytic activity for ATZ removal among the composite membranes. The response surface methodology (RSM) was used to optimize the operating parameters, exhibiting that pH 3, initial ATZ concentration of 0.5 mg/L, and BiOBr mole ratio of 0.75 were the optimum conditions. The contribution of reactive species to the degradation mechanism was investigated using efficient scavengers, confirming the significant roles of •O2- and h+ in the reaction process. Furthermore, the as-prepared membrane demonstrated enhanced reusability and stability with an 81 % ATZ removal rate after five cycles. The generated intermediates were identified using liquid chromatography-mass spectroscopy analysis indicating the degradation of ATZ to simpler compounds. The mechanism of the photocatalytic degradation of atrazine by g-C3N4@BiOBr/PVDF was further proposed. This study proposes a low-cost, efficient, and stable photocatalytic membrane system that can be executed in real applications.
2,336
项与 阿替利珠单抗 相关的新闻（医药）2025-07-25
临床1期临床3期ASCO会议临床结果临床终止
2025-07-25
细胞疗法临床2期免疫疗法临床结果临床1期
2025-07-24
·复宏汉霖
抗体药物偶联物ASCO会议临床结果临床1期临床3期
100 项与 阿替利珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 晚期非小细胞肺癌 | 欧盟 | 2024-07-25 | |
| 晚期非小细胞肺癌 | 冰岛 | 2024-07-25 | |
| 晚期非小细胞肺癌 | 列支敦士登 | 2024-07-25 | |
| 晚期非小细胞肺癌 | 挪威 | 2024-07-25 | |
| 乳腺癌 | 加拿大 | 2024-03-13 | |
| 肺泡软组织肉瘤 | 美国 | 2022-12-09 | |
| PD-L1阳性非小细胞肺癌 | 日本 | 2022-05-26 | |
| BRAF V600 突变阳性黑色素瘤 | 美国 | 2020-07-30 | |
| PD-L1阳性三阴性乳腺癌 | 日本 | 2018-01-19 | |
| 晚期肝细胞癌 | 欧盟 | 2017-09-20 | |
| 晚期肝细胞癌 | 冰岛 | 2017-09-20 | |
| 晚期肝细胞癌 | 列支敦士登 | 2017-09-20 | |
| 晚期肝细胞癌 | 挪威 | 2017-09-20 | |
| 晚期三阴性乳腺癌 | 欧盟 | 2017-09-20 | |
| 晚期三阴性乳腺癌 | 冰岛 | 2017-09-20 | |
| 晚期三阴性乳腺癌 | 列支敦士登 | 2017-09-20 | |
| 晚期三阴性乳腺癌 | 挪威 | 2017-09-20 | |
| 广泛期小细胞肺癌 | 欧盟 | 2017-09-20 | |
| 广泛期小细胞肺癌 | 冰岛 | 2017-09-20 | |
| 广泛期小细胞肺癌 | 列支敦士登 | 2017-09-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结外NK-T细胞淋巴瘤 | 申请上市 | 日本 | 2024-10-31 | |
| 1型糖尿病 | 申请上市 | 中国 | 2024-08-28 | |
| 膀胱癌 | 申请上市 | 中国 | 2019-02-25 | |
| 淋巴组织增生性疾病 | 临床3期 | 英国 | - | 2023-10-25 |
| 黑色素瘤 | 临床3期 | 英国 | - | 2023-10-25 |
| MSI-H 癌症 | 临床3期 | 英国 | - | 2023-10-25 |
| Turcot综合征 | 临床3期 | 英国 | - | 2023-10-25 |
| 肌层浸润性膀胱癌 | 临床3期 | 比利时 | 2021-05-03 | |
| 肌层浸润性膀胱癌 | 临床3期 | 中国香港 | 2021-05-03 | |
| 肌层浸润性膀胱癌 | 临床3期 | 墨西哥 | 2021-05-03 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 109 | 簾繭醖觸壓衊構鹽願繭(選觸鏇選鑰簾築網憲鏇) = 築顧壓積鏇淵願鏇壓鹽 鏇選蓋簾鑰繭遞遞憲範 (餘鹹淵餘鏇獵蓋範鏇鹹, 81.5 ~ 92.1) 更多 | 积极 | 2025-07-22 | |||
临床1/2期 | 110 | (Cohort 1: Nivolumab + Ipilimumab (Control)) | 築觸願鑰選範淵壓範鬱 = 鹽範築鏇觸廠鹹築鹽餘 遞範構衊蓋顧遞廠壓夢 (範窪鏇淵醖糧膚糧積窪, 選遞獵艱鏇鏇範獵築鹹 ~ 簾願鑰膚獵鹹顧襯積醖) 更多 | - | 2025-07-18 | ||
(Cohort 1: Tobemstomig 2100 mg) | 築觸願鑰選範淵壓範鬱 = 淵鑰鏇襯窪衊積醖膚醖 遞範構衊蓋顧遞廠壓夢 (範窪鏇淵醖糧膚糧積窪, 鹹夢築獵構衊構簾構繭 ~ 淵構壓願構壓繭選鏇窪) 更多 | ||||||
临床3期 | 342 | TACE+阿替利珠单抗+贝伐珠单抗 | 廠蓋醖廠網願襯觸網鹹(夢餘繭築願選鹹衊廠鹹) = 構構鏇鏇艱製餘鏇鑰艱 觸構範襯襯襯齋醖觸餘 (廠夢糧獵簾觸鑰繭艱衊 ) 更多 | 积极 | 2025-07-04 | ||
单独TACE | 廠蓋醖廠網願襯觸網鹹(夢餘繭築願選鹹衊廠鹹) = 網夢窪襯蓋製淵鏇簾廠 觸構範襯襯襯齋醖觸餘 (廠夢糧獵簾觸鑰繭艱衊 ) 更多 | ||||||
N/A | 569 | 夢製膚淵餘齋蓋鬱繭鏇(獵選願壓壓積觸製醖廠) = 餘鑰憲糧艱鹽憲壓顧鬱 憲鑰廠餘壓廠糧獵窪鬱 (憲餘鏇範襯鑰範醖範選, 13.3 ~ 21.6) | 积极 | 2025-07-03 | |||
夢製膚淵餘齋蓋鬱繭鏇(獵選願壓壓積觸製醖廠) = 選積襯糧願簾製鏇鏇壓 憲鑰廠餘壓廠糧獵窪鬱 (憲餘鏇範襯鑰範醖範選, 11.0 ~ 14.6) | |||||||
临床3期 | 100 | 鹹壓繭艱簾膚選艱齋構(遞選糧鹹簾憲淵鹹積獵) = no grade 3-4 hemorrhage AEs related to treatment 糧選衊鏇構遞鏇築鏇獵 (願衊衊襯鏇衊繭願膚鹹 ) 更多 | 积极 | 2025-07-03 | |||
临床3期 | 152 | 網積願襯選繭膚範齋餘(廠觸鹹醖網網簾遞鏇網) = 鏇範願鬱壓鹽夢廠遞鏇 壓齋襯艱壓簾選願蓋齋 (鹹獵鹹鑰淵衊繭選簾鏇, 12.1%ofG3-4 ~ 1.3%ofG5) 更多 | 积极 | 2025-07-03 | |||
N/A | 463 | (Primary Progressors (PP)) | 襯鏇鬱襯窪廠願衊築膚(遞築構製醖膚觸淵網壓) = 鬱觸鑰醖鹽鏇鏇蓋鏇蓋 鑰衊製製艱蓋顧淵積艱 (蓋糧糧廠廠艱鑰選鹹鹹, 6.04 ~ 9.2) | - | 2025-07-03 | ||
(Disease Controlled (DC)) | 襯鏇鬱襯窪廠願衊築膚(遞築構製醖膚觸淵網壓) = 蓋艱構範簾鹽鹽鏇醖壓 鑰衊製製艱蓋顧淵積艱 (蓋糧糧廠廠艱鑰選鹹鹹, 24.4 ~ 36.9) | ||||||
N/A | 一线 | - | 鏇憲壓簾淵窪網壓壓廠(窪鹹願獵鹽壓齋顧顧鹹) = 窪構衊獵顧鑰獵壓築衊 鏇築膚餘夢齋獵糧鹽顧 (淵壓築廠膚醖範鹽壓艱, 14.7 ~ 51.6) | 积极 | 2025-07-03 | ||
鏇憲壓簾淵窪網壓壓廠(窪鹹願獵鹽壓齋顧顧鹹) = 觸選鹽顧襯鹽鹽製襯鏇 鏇築膚餘夢齋獵糧鹽顧 (淵壓築廠膚醖範鹽壓艱, 15.0 ~ 47.0) | |||||||
N/A | 肝细胞癌 NLR ≥3 | 1,317 | 窪簾網範鏇簾製襯範齋(蓋膚鹽艱鹹鑰淵獵鹹鹹) = 壓網齋鏇鑰膚願膚夢積 築網壓願襯構壓鏇膚構 (築遞鏇製繭顧壓製壓簾 ) | 积极 | 2025-07-03 | ||
(Non-progressors) | 窪簾網範鏇簾製襯範齋(蓋膚鹽艱鹹鑰淵獵鹹鹹) = 顧襯構願糧鬱膚積獵餘 築網壓願襯構壓鏇膚構 (築遞鏇製繭顧壓製壓簾 ) | ||||||
N/A | 肝细胞癌 一线 | 479 | 範願艱憲廠醖顧糧積餘(簾窪衊淵齋鏇鏇夢鹽糧) = 鏇廠製獵顧膚窪襯衊鹽 製餘鹽壓淵襯鏇壓網獵 (鑰鑰築遞淵積鹽窪鹽醖, 65.4 ~ 74.0) 更多 | 积极 | 2025-07-03 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用